{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:11:42Z","timestamp":1788948702750,"version":"build-2803163510"},"reference-count":76,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The rise in carbapenem resistance is well documented, but a less conspicuous trend has received far less attention: the gradual upward shift in minimum inhibitory concentration (MIC) values among isolates that remain phenotypically \u201csusceptible.\u201d We propose the term carbapenem floor for this phenomenon: an intermediate zone in which standard dosing regimens become progressively less reliable at achieving target exposure, yet which remains invisible to breakpoint-based surveillance; we present this as a hypothesis-generating framework consistent with existing pharmacokinetic and epidemiological evidence rather than as an empirically established trend, since no systematic longitudinal quantification of carbapenem MIC drift has yet been undertaken. Because carbapenems exhibit time-dependent killing and their pharmacokinetic\/pharmacodynamic (PK\/PD) target has MIC as its denominator, even a shift within the susceptible range can substantially reduce target attainment; augmented renal clearance in critically ill patients deepens this erosion. This review integrates resistance surveillance evidence with PK\/PD principles to evaluate prolonged infusion, loading doses, therapeutic drug monitoring (TDM), and empirical protocols derived from population pharmacokinetic models and local MIC distributions, examining for each the evidence and the practical constraints. We also consider the reverse relationship: failure to attain PK\/PD targets appears to select for elevated MICs, suggesting that dosing practice may contribute to resistance selection and potentially influence resistance epidemiology, not only respond to it. Extending antibiogram reporting to include MIC distributions, and translating those data into dosing protocols through antimicrobial stewardship, is a feasible priority where TDM infrastructure is limited.<\/jats:p>","DOI":"10.3390\/antibiotics15090885","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:24:02Z","timestamp":1788945842000},"page":"885","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rising Carbapenem MICs and Clinical Dose Optimization: Bridging Resistance Surveillance and Pharmacokinetic\/Pharmacodynamic Strategies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0085-7470","authenticated-orcid":false,"given":"H\u00fclya","family":"Ar\u0131k","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Near East University, 99138 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jgar.2024.03.020","article-title":"Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018\u20132022","volume":"37","author":"Wise","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2047-2994-2-6","article-title":"The rise of carbapenem resistance in Europe: Just the tip of the iceberg?","volume":"2","author":"Magiorakos","year":"2013","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3201\/eid2804.211975","article-title":"Increasing antimicrobial resistance in World Health Organization Eastern Mediterranean Region, 2017\u20132019","volume":"28","author":"Talaat","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10096-024-04990-w","article-title":"Dose optimization of piperacillin\/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in T\u00fcrkiye","volume":"44","author":"Buyukyanbolu","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Luo, J., Liu, J., Lin, H., Yang, Y., Chen, C., Chen, J., Zhong, H., and Zhang, S. (2025). Optimization of meropenem dosing regimens in critically ill patients with augmented renal clearance. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1550053"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Xu, W., Shang, L., Li, X., Yu, J., Shen, J., Li, Y., He, Q., Chen, L., Wang, D., and Wei, Y. (2026). Current progress in antibacterial agents for carbapenem-resistant Enterobacterales. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1796557"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Caliskan-Aydogan, O., and Alocilja, E.C. (2023). A review of carbapenem resistance in Enterobacterales and its detection techniques. Microorganisms, 11.","DOI":"10.3390\/microorganisms11061491"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jgar.2021.02.033","article-title":"Prevalence and molecular epidemiology of carbapenem-resistant Gram-negative bacilli and their resistance determinants in the Eastern Mediterranean Region over the last decade","volume":"25","author":"Sleiman","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dkaa447","article-title":"IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort","volume":"76","author":"Shropshire","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Piotrowski, M., Alekseeva, I., Arnet, U., and Y\u00fccel, E. (2024). Insights into the rising threat of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa epidemic infections in Eastern Europe: A systematic literature review. Antibiotics, 13.","DOI":"10.3390\/antibiotics13100978"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Miftode, I.L., Radu, V.D., Jigoranu, R.A., Leca, D.A., Prepeliuc, C.S., Pasare, M.A., Miftode, R.S., Grigoriu, M.G., Paranga, T.G., and Miftode, E.G. (2026). Novel insights into carbapenem resistance: Mechanisms, diagnostics, and future directions. Antibiotics, 15.","DOI":"10.3390\/antibiotics15030270"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00451-25","DOI":"10.1128\/jcm.00451-25","article-title":"The shift from \u201cMIC-Only\u201d back to carbapenemase testing among carbapenem-resistant Enterobacterales: What clinical laboratories need to know about updated CLSI guidance","volume":"64","author":"Simner","year":"2026","journal-title":"J. Clin. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","article-title":"Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections\u2014A systematic review and meta-analysis","volume":"24","author":"Diaz","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jgar.2017.04.007","article-title":"Evaluation of vancomycin MIC creep in Staphylococcus aureus","volume":"10","author":"Diaz","year":"2017","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_15","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2026). Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 16.0, EUCAST. Available online: https:\/\/www.eucast.org\/fileadmin\/eucast\/pdf\/breakpoints\/v_16.0_Breakpoint_Tables.pdf."},{"key":"ref_16","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2025). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [35th ed.]. CLSI supplement M100."},{"key":"ref_17","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2024). Breakpoints Eliminated from CLSI Document M100 Since 2010, CLSI. Available online: https:\/\/clsi.org\/media\/xuqbrtsn\/clsi-m100_archived_drugs_table_20241213.pdf."},{"key":"ref_18","first-page":"23","article-title":"Novel and revised terms in the EUCAST 2019 guideline: Susceptible, increased exposure and area of technical uncertainty","volume":"8","author":"Duman","year":"2019","journal-title":"Mediterr. J. Infect. Microbes Antimicrob."},{"key":"ref_19","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2026, September 06). EUCAST to Review Carbapenem Breakpoints [News Item], 31 July 2025; Review of Carbapenem, Carbapenem-Beta-Lactamase Inhibitor and Ceftazidime-Avibactam Breakpoints [News Item]. Available online: https:\/\/www.eucast.org\/news-detail\/eucast-to-review-carbapenem-breakpoints\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00203-19","DOI":"10.1128\/JCM.00203-19","article-title":"Understanding and addressing CLSI breakpoint revisions: A primer for clinical laboratories","volume":"57","author":"Humphries","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/jac\/dkz226","article-title":"Inoculum effect of \u03b2-lactam antibiotics","volume":"74","author":"Lenhard","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e01540-25","DOI":"10.1128\/mbio.01540-25","article-title":"The carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales","volume":"16","author":"Taylor","year":"2025","journal-title":"mBio"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/jac\/dkae283","article-title":"Role of volume and inoculum in MIC assessment: A study with meropenem and Klebsiella pneumoniae","volume":"79","author":"Alieva","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01170-25","DOI":"10.1128\/aac.01170-25","article-title":"Molecular and pharmacodynamic insights into \u03b2-lactam therapy for high-inoculum Enterobacter cloacae complex infections","volume":"69","author":"Gray","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/511864","article-title":"Analysis and presentation of cumulative antibiograms: A new consensus guideline from the Clinical and Laboratory Standards Institute","volume":"44","author":"Hindler","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e03939-22","DOI":"10.1128\/spectrum.03939-22","article-title":"Estimated impact of low isolate numbers on the reliability of cumulative antibiogram data","volume":"11","author":"Tran","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"ofad305","DOI":"10.1093\/ofid\/ofad305","article-title":"Optimizing the use of beta-lactam antibiotics in clinical practice: A test of time","volume":"10","author":"Tilanus","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","article-title":"Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: A systematic review and meta-analysis","volume":"28","author":"Gatti","year":"2024","journal-title":"Crit. Care"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hefny, F., Stuart, A., Kung, J.Y., and Mahmoud, S.H. (2022). Prevalence and risk factors of augmented renal clearance: A systematic review and meta-analysis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020445"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: A systematic review","volume":"57","author":"Barrasa","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/phar.1653","article-title":"Implications of augmented renal clearance on drug dosing in critically ill patients: A focus on antibiotics","volume":"35","author":"Hobbs","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: A systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit. Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CCM.0000000000000029","article-title":"Augmented renal clearance in the ICU: Results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations","volume":"42","author":"Udy","year":"2014","journal-title":"Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"106569","DOI":"10.1016\/j.ijantimicag.2022.106569","article-title":"Recommended antibiotic dosage regimens in critically ill patients with augmented renal clearance: A systematic review","volume":"59","author":"Silva","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/CCM.0000000000007089","article-title":"Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2026","volume":"54","author":"Prescott","year":"2026","journal-title":"Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: The MERCY randomized clinical trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial (BLING I)","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis (BLING II)","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/17511437251396871","article-title":"Continuous versus intermittent beta-lactam antibiotic infusions in critically ill patients: The UK cohort of the BLING III trial","volume":"27","author":"Barton","year":"2026","journal-title":"J. Intensive Care Soc."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, Y., Gao, M., Zhang, M., Li, Y., Wang, D., Li, X., Zhang, C., Fu, Y., and Li, H. (2025). Continuous vs. intermittent meropenem infusion in critically ill patients with sepsis: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1580116"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/jac\/dkq044","article-title":"Stability of meropenem and doripenem solutions for administration by continuous infusion","volume":"65","author":"Berthoin","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0000000000000054","article-title":"Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures","volume":"36","author":"Franceschi","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"ref_45","first-page":"236","article-title":"The stability of generic meropenem in tropical countries","volume":"7","author":"Katip","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15593258211059325","DOI":"10.1177\/15593258211059325","article-title":"Influence of concentration and temperature on stability of imipenem focused on solutions for extended infusion","volume":"19","author":"Sornsuvit","year":"2021","journal-title":"Dose Response"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Manning, L., Wright, C., Ingram, P.R., Whitmore, T.J., Heath, C.H., Manson, I., Page-Sharp, M., Salman, S., Dyer, J., and Davis, T.M.E. (2014). Continuous infusions of meropenem in ambulatory care: Clinical efficacy, safety and stability. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102023"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijantimicag.2010.06.043","article-title":"Stability of doripenem, imipenem and meropenem at elevated room temperatures","volume":"37","author":"Keel","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"105825","DOI":"10.1016\/j.ijantimicag.2019.10.006","article-title":"Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe","volume":"55","author":"Delattre","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_50","first-page":"283","article-title":"Stability of generic brands of meropenem reconstituted in isotonic saline","volume":"81","author":"Carlier","year":"2015","journal-title":"Minerva Anestesiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/ciac506","article-title":"Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: A systematic review and meta-analysis","volume":"75","author":"Ashok","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: A multicentre randomised clinical trial (DOLPHIN)","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/cid\/ciad150","article-title":"\u03b2-Lactam therapeutic drug monitoring in critically ill patients","volume":"76","author":"Zeggil","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"106931","DOI":"10.1016\/j.ijantimicag.2023.106931","article-title":"Which patients benefit from model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin at the ICU?","volume":"62","author":"Ewoldt","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: A randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Abdulla, A., Ewoldt, T.M.J., Hunfeld, N.G.M., Muller, A.E., Rietdijk, W.J.R., Polinder, S., van Gelder, T., Endeman, H., and Koch, B.C.P. (2020). The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: The DOLPHIN trial protocol of a multi-centre randomised controlled trial. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-4781-x"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Alshaer, M.H., Maranchick, N.F., Maguigan, K.L., Shoulders, B.R., Mousa, M.J., Murray, M., Ashton, J., Alexander, K., Santevecchi, B.A., and DeSear, K. (2025). Impact of timing of beta-lactam therapeutic drug monitoring and therapy adjustment in critically ill patients. Antibiotics, 14.","DOI":"10.3390\/antibiotics14050463"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"115945","DOI":"10.1016\/j.diagmicrobio.2023.115945","article-title":"Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States medical centers (2018\u20132022)","volume":"106","author":"Sader","year":"2023","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s10096-023-04647-0","article-title":"Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland","volume":"42","author":"Nordmann","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sophonsri, A., Kalu, M., and Wong-Beringer, A. (2024). Comparative in vitro activity of ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam against carbapenem-resistant clinical isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa. Antibiotics, 13.","DOI":"10.3390\/antibiotics13050416"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Bonnin, R.A., Bernabeu, S., Emeraud, C., Naas, T., Girlich, D., Jousset, A.B., and Dortet, L. (2023). In vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010102"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Maranchick, N.F., Webber, J., Alshaer, M.H., Felton, T.W., and Peloquin, C.A. (2023). Impact of beta-lactam target attainment on resistance development in patients with Gram-negative infections. Antibiotics, 12.","DOI":"10.3390\/antibiotics12121696"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e0104225","DOI":"10.1128\/aac.01042-25","article-title":"Targeting Pseudomonas aeruginosa resistance at the exposure frontier: A population PK\/PD blueprint for ceftolozane\/tazobactam continuous infusion","volume":"69","author":"Cojutti","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gatti, M., and Pea, F. (2026). Raising the bar of PK\/PD target attainment of beta-lactams in daily clinical practice: An effective strategy to overcome resistance development to novel beta-lactams?. Infect. Dis. Rep., 18.","DOI":"10.3390\/idr18010003"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00663-24","DOI":"10.1128\/aac.00663-24","article-title":"In vivo selection of carbapenem resistance during persistent Klebsiella pneumoniae sequence type 395 bloodstream infection due to OmpK36 deletion","volume":"68","author":"Strahilevitz","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lee, Y.Q., Ponnampalavanar, S.S.L.S., Chong, C.W., Karunakaran, R., Vellasamy, K.M., Jabar, K.A., Kong, Z.X., Lau, M.Y., and Teh, C.S.J. (2022). Characterisation of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae based on their clinical and molecular profile in Malaysia. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111670"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e0014825","DOI":"10.1128\/jb.00148-25","article-title":"Molecular characterization and resistance mechanisms of ertapenem-non-susceptible carbapenem-resistant Klebsiella pneumoniae co-harboring ESBLs or AmpC enzymes with porin loss or efflux pump overexpression","volume":"207","author":"Su","year":"2025","journal-title":"J. Bacteriol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lee, Y.Q., Ponnampalavanar, S.S.L.S., Wong, J.H., Kong, Z.X., Ngoi, S.T., Karunakaran, R., Lau, M.Y., Jabar, K.A., and Teh, C.S.J. (2024). Investigation on the mechanisms of carbapenem resistance among the non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1464816"},{"key":"ref_70","unstructured":"Centers for Disease Control and Prevention (2026, September 06). Core Elements of Hospital Antibiotic Stewardship Programs, Available online: https:\/\/www.cdc.gov\/antibiotic-use\/hcp\/core-elements\/hospital.html."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1017\/ash.2021.210","article-title":"Interventions to optimize antimicrobial stewardship","volume":"1","author":"Tinker","year":"2021","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chitatanga, R., Yiwombe, C., Divala, O., Msokera, M.P., Banda, E., Chadwala, H., Gilmon, M.W., Kaminyoghe, W., Chibwe, I., and Milala, H. (2025). A baseline assessment of antimicrobial stewardship core element implementation in selected public hospitals in Malawi: Findings from the 2023 National Program Audit. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1588778"},{"key":"ref_73","unstructured":"European Centre for Disease Prevention and Control (2024). Antimicrobial Resistance in the EU\/EEA (EARS-Net): Annual Epidemiological Report 2023, ECDC."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5505\/TurkHijyen.2016.82653","article-title":"Antibiotic resistance rates of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae isolated from a university-affiliated hospital in North Cyprus","volume":"73","author":"Ruh","year":"2016","journal-title":"T\u00fcrk Hij. Den. Biyol. Derg."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Mermer, S., and \u00c7a\u011flayan, E. (2026). Prevalence, clinical characteristics, and antibiotic resistance of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in T\u00fcrkiye (2023\u20132025). BMC Microbiol., 26.","DOI":"10.1186\/s12866-026-04727-z"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Tsalidou, M., Stergiopoulou, T., Bostanitis, I., Nikaki, C., Skoumpa, K., Koutsoukou, T., and Papaioannidou, P. (2023). Surveillance of antimicrobial resistance and multidrug resistance prevalence of clinical isolates in a regional hospital in Northern Greece. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111595"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/9\/885\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:03:53Z","timestamp":1788948233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/9\/885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":76,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["antibiotics15090885"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15090885","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}